220977-91-3

Basic information

• Product Name: N-[1(R)-[N-(3-Amino-2-hydroxypropyl)carbamoyl]-2-naphthylethyl]-4-(4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-5-yl)butyramide hydrochloride
• Synonyms: S-37435
• CAS NO: 220977-91-3
• Molecular Formula: C₂₉H₃₅ClN₄O₄S
• Molecular Weight: 571.1437
• Mol File: 220977-91-3.mol

Chemical Properties

• CAS DataBase Reference: N-[1(R)-[N-(3-Amino-2-hydroxypropyl)carbamoyl]-2-naphthylethyl]-4-(4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-5-yl)butyramide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-[1(R)-[N-(3-Amino-2-hydroxypropyl)carbamoyl]-2-naphthylethyl]-4-(4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-5-yl)butyramide hydrochloride(220977-91-3)
• EPA Substance Registry System: N-[1(R)-[N-(3-Amino-2-hydroxypropyl)carbamoyl]-2-naphthylethyl]-4-(4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-5-yl)butyramide hydrochloride(220977-91-3)

Safety Data

• Hazardous Substances Data: 220977-91-3(Hazardous Substances Data)

Upstream product

• 383187-87-9 4-(4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl)butanoic acid ethyl ester 
• 383187-86-8 4-(4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl)butanoic acid 
• 53454-43-6 2,3-dihydro-1,5-benzothiazepine-4(5H)-one 
• 383187-95-9 N-[1-(R)-(3-tert-butoxycarbonylamino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl)butyramide 
• 289050-81-3 CBZ-D-3-(2-naphthyl)alanyl-3-amino-2-hydroxypropyl-carbamic acid t-butylester 
• 289050-83-5 N-[3-(tert-butoxycarbonylamino)-2-hydroxypropyl]-2-(R)-amino-3-(naphthalen-2-yl)propionamide 
• 143218-10-4 Cbz-D-naphthylalanine 

Relevant articles and documents

N-acylated lipophilic amino acid derivatives

Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceuticall

Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues

In the joint experimental and computational efforts reported here to obtain novel chemical entities as growth hormone secretagogues (GHSs), a small database of peptides and non-peptides known to have GHS activity was used to generate and assess a 3D pharmacophore for this activity. This pharmacophore was obtained using a systematic and efficient procedure, "DistComp", developed in our laboratory. The 3D pharmacophore identified was then used to search 3D databases to explore chemical structures that could be novel GHSs. A number of these were chosen for synthesis and assessment of their ability to release growth hormone (GH) from rat pituitary cells. Among the compounds tested, those with a benzothiazepin scaffold were discovered with micromolar activity. To facilitate lead optimization, a second program, a site-dependent fragment QSAR procedure was developed. This program calculates a library of chemical and physical properties of "fragments" or chemical components in a known pharmacophore and determines which, if any, of these properties are important for the observed activity. The combined use of the 3D pharmacophore and the results of the site-dependent fragment QSAR analysis led to the discovery and synthesis of a novel series of potent GHSs, a number of which had nanomolar in vitro activity.